Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...
Set to enter hospice care, a patient with idiopathic multicentric Castleman’s disease is now in remission after treatment with a medication identified by an AI-guided analysis ...
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...